PFE Pfizer
- 29.215
- +0.055+0.19%
Pfizer News
Pfizer Inc. (PFE): A Bull Case Theory
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says
"Florida Discourages Use Of MRNA Covid Vaccines In Older Adults; In Updated Guidance To Health Care Providers, Florida Health Officials Advise That "Non-mRNA Covid-19 Vaccines And Treatment" Should Be Prioritized" - NBC News
US stocks are mixed, with vaccine concept stocks rising and falling, novavax (NVAX.US) up more than 5.4%.
As of press time, the stock has risen more than 5.4%, closing at $12.57.
Novavax COVID-19 Vaccines Now Available
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Pfizer Options Spot-On: On September 12th, 128.59K Contracts Were Traded, With 3.02 Million Open Interest
Is It Finally Time to Get Excited About Pfizer Stock?
Express News | North Dakota Judge Overturns State's Abortion Ban, Making Abortion Legal In The State
Unusual Options Activity: EQT, AR and Others Attract Market Bets, EQT V/OI Ratio Reaches 722.1
Express News | Pfizer Down 2.2%, Novavax Down 8.5%
Express News | Shares of Some U.S. Vaccine Makers Fall in Early Trade
Moderna (MRNA.US) sales expectations for 2025 disappointed the market.
Moderna expects its sales to be between $2.5 billion and $3.5 billion in 2025.
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com
Is Pfizer Inc. (PFE) The Most Buzzing Stock To Buy Now?
Pfizer Options Spot-On: On September 11th, 95,976 Contracts Were Traded, With 2.98 Million Open Interest
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Pfizer (PFE) Upgraded to Buy: What Does It Mean for the Stock?
Analysis
Price Target
No Data
No Data
